Inclisiran: Efficacy in Real World—Systematic Review and Meta-Analysis
Journal of Clinical Medicine · 12.06.2025 · 14 (12) · 4163
DOI: 10.3390/jcm14124163 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.06.2025. Verfasst von Álvaro Rodrigo Alaíz und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Valladolid University, 47003 Valladolid, Spain. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Inclisiran is a novel lipid-lowering agent targeting PCSK9 via small interfering RNA (siRNA) technology. While clinical trials such as the ORION studies have demonstrated significant reductions in low-density lipoprotein cholesterol (c-LDL), real-world data (RWD) often differ due to variations in patient populations and clinical practices.
Methods
This systematic review and meta-analysis adhered to PRISMA guidelines. A comprehensive search was conducted in MEDLINE for real-world studies evaluating inclisiran’s efficacy in reducing c-LDL. Articles meeting predefined inclusion criteria were assessed for quality and bias using RTI Item Bank. Data transformations were applied to harmonize median and IQR values to means and standard deviations for meta-analytic synthesis using RevMan 5.4.
Results
A total of 3774 articles were identified, of which 7 studies comprising 1454 patients met the inclusion criteria. The meta-analysis revealed an average c-LDL reduction of 42.77% (95% CI: 37.42–48.12%). The subgroup analysis indicated greater reductions in patients receiving inclisiran alongside statins (45.67%; 95% CI: 36.64–54.71%) compared to monotherapy (37.53%; 95% CI: 29.91–45.15%). Discrepancies with clinical trials (e.g., 52% reduction in ORION studies) were attributed to baseline c-LDL differences and real-world adherence.
Conclusions
Inclisiran demonstrates robust efficacy in real-world settings, achieving significant c-LDL reductions with a convenient dosing schedule. However, the observed discrepancies with clinical trials highlight the need for further RWD studies to bridge gaps in effectiveness and optimize therapeutic outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Valladolid University, 47003 Valladolid, Spain.
- Internal Medicine Unit, Río Hortega University Hospital, 47003 Valladolid, Spain.
- Cardiology Unit, San Carlos University, 28040 Madrid, Spain.
- Cardiology Unit, Río Hortega University Hospital, 47012 Valladolid, Spain.
- Cardiology Unit, Salamanca University Hospital, 37007 Salamanca, Spain.
ORCID-Profile: Álvaro Rodrigo Alaíz, David González Calle, José Pablo Miramontes-González
Zitieren
APA
Alaíz, Á. R., Gudino, L. C., de la Isla, L. P., Pardo, H. G., Calle, D. G., & Miramontes-González, J. P. (2025). Inclisiran: Efficacy in Real World—Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 14(12), 4163. https://doi.org/10.3390/jcm14124163
Vancouver
Alaíz ÁR, Gudino LC, de la Isla LP, Pardo HG, Calle DG, Miramontes-González JP. Inclisiran: Efficacy in Real World—Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2025;14(12):4163. doi:10.3390/jcm14124163
BibTeX
@article{Alaz2025,
author = {Alaíz, Álvaro Rodrigo and Gudino, Luis Corral and de la Isla, Leopoldo Pérez and Pardo, Héctor García and Calle, David González and Miramontes-González, José Pablo},
title = {Inclisiran: Efficacy in Real World—Systematic Review and Meta-Analysis},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {12},
pages = {4163},
doi = {10.3390/jcm14124163}
}
EUVIMED